Opinicus Capital Inc. Boosts Stock Position in Bristol Myers Squibb Company $BMY

Opinicus Capital Inc. lifted its position in Bristol Myers Squibb Company (NYSE:BMY) by 14.4% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 19,327 shares of the biopharmaceutical company’s stock after acquiring an additional 2,426 shares during the period. Opinicus Capital Inc.’s holdings in Bristol Myers Squibb were worth $895,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of BMY. Brighton Jones LLC raised its stake in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new position in shares of Bristol Myers Squibb during the first quarter valued at $2,298,000. Cullen Frost Bankers Inc. increased its holdings in Bristol Myers Squibb by 16.1% during the first quarter. Cullen Frost Bankers Inc. now owns 34,210 shares of the biopharmaceutical company’s stock valued at $2,086,000 after buying an additional 4,742 shares during the period. Graypoint LLC boosted its position in Bristol Myers Squibb by 21.4% during the first quarter. Graypoint LLC now owns 19,421 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 3,423 shares in the last quarter. Finally, Bailard Inc. lifted its position in Bristol Myers Squibb by 25.9% during the first quarter. Bailard Inc. now owns 7,160 shares of the biopharmaceutical company’s stock valued at $437,000 after acquiring an additional 1,472 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on BMY. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a report on Tuesday, August 5th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Scotiabank initiated coverage on Bristol Myers Squibb in a research report on Thursday. They issued a “sector perform” rating and a $45.00 price target for the company. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Finally, Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. Four analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $54.58.

Bristol Myers Squibb Trading Down 4.0%

Shares of BMY opened at $46.67 on Friday. The firm has a market capitalization of $95.00 billion, a P/E ratio of 18.82, a PEG ratio of 2.23 and a beta of 0.33. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The firm’s 50-day moving average is $45.34 and its two-hundred day moving average is $46.70. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. During the same period in the previous year, the company earned $1.80 EPS. Bristol Myers Squibb’s revenue for the quarter was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd were issued a $0.62 dividend. The ex-dividend date was Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.3%. Bristol Myers Squibb’s payout ratio is currently 83.78%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.